Obstructive sleep apnoea with obesity — compounds assessed

§4Compounds assessed

Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.

• Tirzepatide in sleep apnoea

  Dual GIP and GLP-1 receptor agonist (acylated)2 contributing trialsfull monograph

  Apnoea–hypopnoea index reduced by 25.3 events/hour versus 5.3 with placebo in participants not using positive airway pressure — Objective, centrally scored polysomnographic endpoint; two parallel trials with consistent results.

  High
• Liraglutide in sleep apnoea

  GLP-1 receptor agonist (acylated, once-daily)1 contributing trialfull monograph

  Apnoea–hypopnoea index reduced by 12.2 events/hour versus 6.1 with placebo at 32 weeks — Imprecise; substantially smaller effect than reported for tirzepatide.

  Moderate
• Retatrutide in sleep apnoea

  Triple GIP, GLP-1 and glucagon receptor agonist (acylated)1 contributing trialfull monograph

  Not yet reported — Registered but unreported at this assessment cycle.

  Not rated

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine 2022;387(3):205–216. doi:10.1056/NEJMoa2206038 · PMID 35658024

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.